Assertion Contradicted AI assessment confidence: 98% certainty 4/5 debate potential 1/5

Andy Tran: AAVs are the only clinically approved gene therapy vectors

Andy Tran · CRISPR 2.0 and the Future of Gene Therapies · Oct 5, 2019 · at 12:24

Andy Tran of Andreessen Horowitz (a16z) outlines delivery bottlenecks and viral vectors during an a16z presentation on CRISPR 2.0.

0:00 / 0:09exact quote · 9.6s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“To jump in, probably the natural place to start is on the AV side, as these adeno-associated viruses are the only clinically approved vector so far for gene therapy.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

As of October 2019, adeno-associated viruses (AAVs) were the only clinically approved vectors for gene therapy.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

The claim that adeno-associated viruses (AAVs) were the only clinically approved gene therapy vectors as of October 2019 is false. Multiple non-AAV viral vectors had received regulatory approval from major international agencies prior to October 2019. For example, the FDA approved Imlygic (Herpes Simplex Virus-1 vector) in 2015, Kymriah (lentiviral vector) in 2017, and Yescarta (gammaretroviral vector) in 2017. In Europe, the EMA approved Strimvelis (gammaretroviral vector) in 2016 and Zynteglo (lentiviral vector) in May 2019.

FDA approved Imlygic (HSV-1 vector) on October 27, 2015
FDA approved Kymriah (lentiviral vector) on August 30, 2017
FDA approved Yescarta (gammaretroviral vector) on October 18, 2017
EMA approved Strimvelis (gammaretroviral vector) on May 26, 2016

Checked against

[1] nvgct.nl [2] nih.gov [3] amgen.com [4] wikipedia.org [5] nih.gov [6] efim.org [7] wikipedia.org [8] primaryimmune.org

"Zynteglo" EMA approval date lentivirus vector "Gendicine" approval date adenovirus gene therapy "Imlygic" "FDA" approval date herpes simplex vector "Strimvelis" "EMA" approval date retrovirus vector "Kymriah" FDA approval date lentivirus vector "Yescarta" FDA approval date retrovirus vector

assessed as of 2026-07-31

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

adeno-associated viruses gene therapy

⚑ Spot an error? Report it

More from Andy Tran

Prediction Not checkable as stated

Tran predicts 10 to 20 gene therapy approvals annually by 2030

“We're expecting at least 10 to 20 gene therapy approvals per year by the end of the decade.”

Andy Tran Oct 5, 2019 ▶ 2:23 CRISPR 2.0 and the Future of Gene Therapies

Assertion Supported

Andy Tran: Gene Editing Enables Curative Single-Dose Treatments

“Of course, this is certainly a big paradigm shift and very exciting as these technologies have given us the power to precisely target And eliminate the origin of disease, as well as be very curative with just a single dose of the drug.”

Andy Tran Oct 5, 2019 ▶ 1:24 CRISPR 2.0 and the Future of Gene Therapies

Insight

Tran: CRISPR is evolving into a cellular search engine platform

“Instead of just this pair of molecular scissors that everyone talks about, the biggest recent shift in the field is this push towards making CRISPR a search engine platform of the cell.”

Andy Tran Oct 5, 2019 ▶ 6:21 CRISPR 2.0 and the Future of Gene Therapies

Insight

Andy Tran: Gene therapy winners will pair platforms with disease-specific optimization

“Regardless of the type of vector that you're engineering, we believe the winners in the space are the ones that could harness a specific platform and marry it with very thoughtful optimization towards specific disease areas.”

Andy Tran Oct 5, 2019 ▶ 14:55 CRISPR 2.0 and the Future of Gene Therapies

Prediction Not checkable as stated

Tran: Metagenomic mining will uncover genome editing systems beyond CRISPR

“As we continue to mine new metagenomic data of new species, it's not crazy to think that perhaps even CRISPR itself is by no means the final frontier of genome engineering.”

Andy Tran Oct 5, 2019 ▶ 18:46 CRISPR 2.0 and the Future of Gene Therapies

Opinion

Tran: Manufacturing is an overlooked existential threat to gene therapy

“So once you've designed the perfect gene therapy, perhaps one of the most overlooked, but most existential threats to the industry is challenges in manufacturing.”

Andy Tran Oct 5, 2019 ▶ 19:23 CRISPR 2.0 and the Future of Gene Therapies

Andy Tran: AAVs are the only clinically approved gene therapy vectors

More from Andy Tran

Turn any episode into a week of clips.